118 related articles for article (PubMed ID: 30540594)
1. Aurora kinase B inhibitor barasertib (AZD1152) inhibits glucose metabolism in gastric cancer cells.
He J; Qi Z; Zhang X; Yang Y; Liu F; Zhao G; Wang Z
Anticancer Drugs; 2019 Jan; 30(1):19-26. PubMed ID: 30540594
[TBL] [Abstract][Full Text] [Related]
2. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.
Helfrich BA; Kim J; Gao D; Chan DC; Zhang Z; Tan AC; Bunn PA
Mol Cancer Ther; 2016 Oct; 15(10):2314-2322. PubMed ID: 27496133
[TBL] [Abstract][Full Text] [Related]
3. Reactive oxygen species generation and increase in mitochondrial copy number: new insight into the potential mechanism of cytotoxicity induced by aurora kinase inhibitor, AZD1152-HQPA.
Zekri A; Mesbahi Y; Ghanizadeh-Vesali S; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Anticancer Drugs; 2017 Sep; 28(8):841-851. PubMed ID: 28639950
[TBL] [Abstract][Full Text] [Related]
4. P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA.
Grundy M; Seedhouse C; Russell NH; Pallis M
BMC Cancer; 2011 Jun; 11():254. PubMed ID: 21679421
[TBL] [Abstract][Full Text] [Related]
5. Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA.
Marchetti S; Pluim D; van Eijndhoven M; van Tellingen O; Mazzanti R; Beijnen JH; Schellens JH
Invest New Drugs; 2013 Oct; 31(5):1125-35. PubMed ID: 23315030
[TBL] [Abstract][Full Text] [Related]
6. Sequential treatment with aurora B inhibitors enhances cisplatin-mediated apoptosis via c-Myc.
Ma Y; Cao H; Lou S; Shao X; Lv W; Qi X; Liu Y; Ying M; He Q; Yang X
J Mol Med (Berl); 2015 Apr; 93(4):427-38. PubMed ID: 25411027
[TBL] [Abstract][Full Text] [Related]
7. Inhibitor of Aurora Kinase B Induces Differentially Cell Death and Polyploidy via DNA Damage Response Pathways in Neurological Malignancy: Shedding New Light on the Challenge of Resistance to AZD1152-HQPA.
Zekri A; Ghaffari SH; Yaghmaie M; Estiar MA; Alimoghaddam K; Modarressi MH; Ghavamzadeh A
Mol Neurobiol; 2016 Apr; 53(3):1808-1823. PubMed ID: 25752998
[TBL] [Abstract][Full Text] [Related]
8. Significance of AZD1152 as a potential treatment against Aurora B overexpression in acute promyelocytic leukemia.
Ghanizadeh-Vesali S; Zekri A; Zaker F; Zaghal A; Yousefi M; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Ann Hematol; 2016 Jun; 95(7):1031-42. PubMed ID: 27091351
[TBL] [Abstract][Full Text] [Related]
9. Aurora B inhibitor barasertib prevents meiotic maturation and subsequent embryo development in pig oocytes.
Ju S; Peng X; Yang X; Sozar S; Muneri CW; Xu Y; Chen C; Cui P; Xu W; Rui R
Theriogenology; 2016 Jul; 86(2):503-15. PubMed ID: 26993175
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.
Diaz RJ; Golbourn B; Faria C; Picard D; Shih D; Raynaud D; Leadly M; MacKenzie D; Bryant M; Bebenek M; Smith CA; Taylor MD; Huang A; Rutka JT
Oncotarget; 2015 Feb; 6(5):3359-74. PubMed ID: 25739120
[TBL] [Abstract][Full Text] [Related]
11. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
[TBL] [Abstract][Full Text] [Related]
12. Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy.
Porcelli L; Guida G; Quatrale AE; Cocco T; Sidella L; Maida I; Iacobazzi RM; Ferretta A; Stolfa DA; Strippoli S; Guida S; Tommasi S; Guida M; Azzariti A
J Transl Med; 2015 Jan; 13():26. PubMed ID: 25623468
[TBL] [Abstract][Full Text] [Related]
13. Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines.
Baldini E; Tuccilli C; Prinzi N; Sorrenti S; Antonelli A; Gnessi L; Morrone S; Moretti C; Bononi M; Arlot-Bonnemains Y; D'Armiento M; Ulisse S
Endocr Relat Cancer; 2014 Oct; 21(5):797-811. PubMed ID: 25074669
[TBL] [Abstract][Full Text] [Related]
14. Selective inhibition of Aurora A and B kinases effectively induces cell cycle arrest in t(8;21) acute myeloid leukemia.
Qi J; Gao X; Zhong X; Zhang N; Wang R; Zhang H; Pan T; Liu X; Yao Y; Wu Q; Niu M; Xu K
Biomed Pharmacother; 2019 Sep; 117():109113. PubMed ID: 31207577
[TBL] [Abstract][Full Text] [Related]
15. Salivary glands require Aurora Kinase B for regeneration after transient innate immune-mediated injury.
Shaalan A; Proctor G
Sci Rep; 2019 Aug; 9(1):11339. PubMed ID: 31383943
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia.
Dennis M; Davies M; Oliver S; D'Souza R; Pike L; Stockman P
Cancer Chemother Pharmacol; 2012 Sep; 70(3):461-9. PubMed ID: 22864876
[TBL] [Abstract][Full Text] [Related]
17. Aurora kinase B disruption suppresses pathological retinal angiogenesis by affecting cell cycle progression.
Zhu W; Gui X; Zhou Y; Gao X; Zhang R; Li Q; Zhang H; Zhao J; Cui X; Gao G; Tang H; Huan C; Pan D; Song H; Zhou Z; Shen W
Exp Eye Res; 2024 Feb; 239():109753. PubMed ID: 38142764
[TBL] [Abstract][Full Text] [Related]
18. Aurora B expression modulates paclitaxel response in non-small cell lung cancer.
Al-Khafaji AS; Davies MP; Risk JM; Marcus MW; Koffa M; Gosney JR; Shaw RJ; Field JK; Liloglou T
Br J Cancer; 2017 Feb; 116(5):592-599. PubMed ID: 28095398
[TBL] [Abstract][Full Text] [Related]
19. Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe.
Li J; Hong MJ; Chow JP; Man WY; Mak JP; Ma HT; Poon RY
Oncotarget; 2015 Apr; 6(11):9327-40. PubMed ID: 25871386
[TBL] [Abstract][Full Text] [Related]
20. The Potential Contribution of microRNAs in Anti-cancer Effects of Aurora Kinase Inhibitor (AZD1152-HQPA).
Zekri A; Mesbahi Y; Boustanipour E; Sadr Z; Ghaffari SH
J Mol Neurosci; 2018 Aug; 65(4):444-455. PubMed ID: 30051358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]